<DOC>
	<DOC>NCT02946554</DOC>
	<brief_summary>The study will assess the safety of two dose regimens of HepaStem in Patients with ACLF up to Day 28 of the active study period.</brief_summary>
	<brief_title>Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF</brief_title>
	<detailed_description />
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<criteria>Main Diagnosed cirrhosis ACLF Grade 1 or ACLF Grade 2 with no circulatory or respiratory failure. Main Absence of portal vein flow Known or medical history of thrombotic events Gastrointestinal hemorrhage requiring blood transfusion Septic shock or noncontrolled bacterial infection Clinical evidence of aspergilus infection. Circulatory failure Respiratory disordered MELD score &gt; 35. Previous organ transplantation and/or ongoing immunosuppressive treatments. Renal failure due to chronic kidney disease. Clinically significant leftright cardiac shunt.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acute-On-Chronic Liver Failure</keyword>
	<keyword>ACLF</keyword>
</DOC>